Article thumbnail

Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia

By Sonia Mulero-Navarro, Ana Sevilla, Angel C. Roman, Dung-Fang Lee, Sunita L. D’Souza, Sherly Pardo, Ilan Riess, Jie Su, Ninette Cohen, Christoph Schaniel, Nelson A. Rodriguez, Alessia Baccarini, Brian D. Brown, Hélène Cavé, Aurélie Caye, Marion Strullu, Safak Yalcin, Christopher Y. Park, Perundurai S. Dhandapany, Ge Yongchao, Lisa Edelmann, Sawsan Bahieg, Patrick Raynal, Elisabetta Flex, Marco Tartaglia, Kateri A. Moore, Ihor R. Lemischka and Bruce D. Gelb

Abstract

SummarySomatic PTPN11 mutations cause juvenile myelomonocytic leukemia (JMML). Germline PTPN11 defects cause Noonan syndrome (NS), and specific inherited mutations cause NS/JMML. Here, we report that hematopoietic cells differentiated from human induced pluripotent stem cells (hiPSCs) harboring NS/JMML-causing PTPN11 mutations recapitulated JMML features. hiPSC-derived NS/JMML myeloid cells exhibited increased signaling through STAT5 and upregulation of miR-223 and miR-15a. Similarly, miR-223 and miR-15a were upregulated in 11/19 JMML bone marrow mononuclear cells harboring PTPN11 mutations, but not those without PTPN11 defects. Reducing miR-223’s function in NS/JMML hiPSCs normalized myelogenesis. MicroRNA target gene expression levels were reduced in hiPSC-derived myeloid cells as well as in JMML cells with PTPN11 mutations. Thus, studying an inherited human cancer syndrome with hiPSCs illuminated early oncogenesis prior to the accumulation of secondary genomic alterations, enabling us to discover microRNA dysregulation, establishing a genotype-phenotype association for JMML and providing therapeutic targets

Publisher: The Authors. Published by Elsevier Inc.
Year: 2015
DOI identifier: 10.1016/j.celrep.2015.09.019
OAI identifier:

Suggested articles


To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.